Clinical Trials Browser

Phase 2 × Medulloblastoma × Eflornithine × Clear all

NCT04696029 2026-03-02

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Phase 2 Recruiting

Medulloblastoma